Associated Papers
Long QT interval syndrome type 2 caused by a new missense mutation of KCNH2 gene: A case report.
Ma Y et al.
Medicine, 2026
Molecular determinants of HERG potassium channel blockade by domiphen bromide and benzethonium chloride.
Tang F et al.
Pflugers Archiv : European Journal of Physiology, 2025
Harnessing AlphaFold to reveal hERG channel conformational state secrets.
Ngo K et al.
Biorxiv : the Preprint Server for Biology, 2025
Multiplexed Assays of Variant Effect and Automated Patch-clamping Improve KCNH2-LQTS Variant Classification and Cardiac Event Risk Stratification.
O'Neill MJ et al.
Medrxiv : the Preprint Server for Health Sciences, 2024
Impacts of gene variants on drug effects-the foundation of genotype-guided pharmacologic therapy for long QT syndrome and short QT syndrome.
Zhao Z et al.
Ebiomedicine, 2024
Investigating the state dependence of drug binding in hERG channels using a trapped-open channel phenotype.
Thouta S et al.
Scientific Reports, 2018
Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.
Zhang Y et al.
Biochemical Pharmacology, 2016
Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide.
Melgari D et al.
Journal of Molecular and Cellular Cardiology, 2015
The Link between Inactivation and High-Affinity Block of hERG1 Channels.
Wu W et al.
Molecular Pharmacology, 2015
Current pharmacogenomic studies on hERG potassium channels.
He FZ et al.
Trends in Molecular Medicine, 2013
hERG K(+) channels: structure, function, and clinical significance.
Vandenberg JI et al.
Physiological Reviews, 2012
Molecular determinants of hERG potassium channel inhibition by disopyramide.
El Harchi A et al.
Journal of Molecular and Cellular Cardiology, 2012
Molecular determinants for activation of human ether-à-go-go-related gene 1 potassium channels by 3-nitro-n-(4-phenoxyphenyl) benzamide.
Garg V et al.
Molecular Pharmacology, 2011
Block of the hERG channel by bupivacaine: Electrophysiological and modeling insights towards stereochemical optimization.
Sintra Grilo L et al.
European Journal of Medicinal Chemistry, 2011
Stereoselective Inhibition of the hERG1 Potassium Channel.
Grilo LS et al.
Frontiers in Pharmacology, 2010
PD-118057 contacts the pore helix of hERG1 channels to attenuate inactivation and enhance K+ conductance.
Perry M et al.
Proceedings of the National Academy of Sciences of the United States of America, 2009
Molecular determinants of hERG channel block by terfenadine and cisapride.
Kamiya K et al.
Journal of Pharmacological Sciences, 2008
The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-à-go-go-related gene (hERG) potassium channels.
Tang Q et al.
British Journal of Pharmacology, 2008
hERG potassium channels and the structural basis of drug-induced arrhythmias.
Mitcheson JS
Chemical Research in Toxicology, 2008
Drug block of the hERG potassium channel: insight from modeling.
Stansfeld PJ et al.
Proteins, 2007
Structural requirements of human ether-a-go-go-related gene channels for block by bupivacaine.
Siebrands CC et al.
Anesthesiology, 2007
Molecular determinants of HERG channel block.
Kamiya K et al.
Molecular Pharmacology, 2006
Molecular mechanisms for drug interactions with hERG that cause long QT syndrome.
Stansfeld PJ et al.
Expert Opinion on Drug Metabolism & Toxicology, 2006
The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ et al.
Molecular Pharmacology, 2004
Structural determinants of HERG channel block by clofilium and ibutilide.
Perry M et al.
Molecular Pharmacology, 2004
Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.
Ficker E et al.
Molecular Pharmacology, 2001
HERG K+ channels: friend and foe.
Vandenberg JI et al.
Trends in Pharmacological Sciences, 2001
Mutational analysis of block and facilitation of HERG current by a class III anti-arrhythmic agent, nifekalant.
Hosaka Y et al.
Channels (austin, Tex.), 0